CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Hikma appoints Umang Vohra as a Director

By NASDAQ Dubai

Hikmaappoints Umang Vohra as a Director

London, 9 November 2026 - Hikma Pharmaceuticals PLC (Hikma) announces the appointment of Umang Vohra as an independentNon-Executive Director with effect from 1 December 2026. Umang will also beappointed a member of the Audit Committee and Nomination and GovernanceCommittee with effect from 1 December 2026.

Commenting on theappointment, Victoria Hull, Chair said “I am delighted to welcome Umang to theHikma Board. Umang is an experienced CEO with deep knowledge of the genericpharmaceutical market and an impressive track record in growth, innovation, portfoliodevelopment and transformation. His extensive international experience,particularly in North America, will bring valuable perspective to the Board.”

About UmangVohra

Umang currentlyserves as Chair and Chief Executive Officer of Cohance Lifesciences Limited, anend-to-end innovation-led CDMO business listed in India. In this role hedivides his time between the US and India.

Umang is also anindependent board member of AGS Health, a revenue cycle management companyregistered in India.

Umang previouslyserved as CEO of Cipla Limited and is credited with transforming Cipla into adiversified global pharmaceutical enterprise. Earlier in his career, Umang heldsenior finance, business development and operational leadership roles at Dr.Reddy’s Laboratories Limited, including as CFO and Head of its North Americanbusiness.

Enquiries:

Hikma Pharmaceuticals PLC

Susan Ringdal: EVP, Strategic Planning and Global Affairs+44 (0) 20 7399 2760

Helen Middlemist, Group Company Secretary +44 (0) 20 73992760

Thisannouncement is made in accordance with Listing Rule 6.4.6. There is no furtherinformation to be disclosed under the requirements of Listing Rule 6.4.8 of theListing Rules in relation to Umang Vohra’s appointment.

About Hikma:

Hikma helps put better health within reach everyday for millions of people around the world. For more than 45 years, we've beencreating high-quality medicines and making them accessible to the people whoneed them. Headquartered in the UK, we are a global company with a localpresence across North America, the Middle East and North Africa (MENA) andEurope, and we use our unique insight and expertise to transform cutting-edgescience into innovative solutions that transform people's lives. We're committedto our customers, and the people they care for, and by thinking creatively andacting practically, we provide them with a broad range of branded andnon-branded generic medicines. Together, our 9,500 colleagues are helping toshape a healthier world that enriches all our communities. We are a leadinglicensing partner, and through our venture capital arm, are helping bringinnovative health technologies to people around the world. For moreinformation, please visit: www.hikma.com

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai:HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P andBBB/stable Fitch)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.